Publications found:
12,947
Sort by:
Monofilament (Over 1mm) Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 664.00
... 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for ... key questions such as: What is the size of the monofilament (> 1mm) market in Japan? How is the market divided into different product segments? Which ...
October 2013
14 pages
Plastic Headgear Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 664.00
... 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key ... key questions such as: What is the size of the plastic headgear market in Japan? How is the market divided into different product segments? Which ...
October 2013
13 pages
2014 Opportunities in the Japanese Clinical Chemistry and Immunodiagnostics Markets
US$ 6,080.00
... 600. DataPack (test volumes, sales forecasts, supplier shares) $4,900. “2014 Opportunities in the Japanese Clinical Chemistry and Immunodiagnostics Markets” is a new strategic ... next five years. The report explores future trends in the Japanese market; provides estimates of the specimen, test and sales volumes ...
September 2013
559 pages
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN
US$ 250.00
Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...
September 2013
7 pages
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN
US$ 250.00
Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...
September 2013
7 pages
Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain
US$ 140.00
... Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013 ... detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug ...
September 2013
6 pages
Lime Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 653.00
... 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for ... ANSWERS KEY QUESTIONS SUCH AS: What is the size of the lime market in Japan? How is the market divided into different product segments? Which products ...
August 2013
14 pages
Glass Tube Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 653.00
... 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for ... KEY QUESTIONS SUCH AS: What is the size of the glass tube market in Japan? How is the market divided into different product segments? Which products ...
August 2013
15 pages
Dolomite Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 653.00
... until 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for ... ANSWERS KEY QUESTIONS SUCH AS: What is the size of the dolomite market in Japan? How is the market divided into different product segments? Which ...
August 2013
13 pages
KYORIN, Flutiform Will Make its Japanese Debut Soon - A game changer for Kyorin!
US$ 200.00
... PAFSC committee recommendation, Flutiform (Fluticasone propionate + formoterol) fixed dose combination is likely to get Japanese approval in September. It will be the third ... MDI (Chart 1) and Symbicort Trubohaler. Key advantage with Flutiform is its faster onset of action which gives rapid relief from ...
August 2013
5 pages
Wood Based Panel Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 653.00
... until 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for ... KEY QUESTIONS SUCH AS: What is the size of the wood based panel market in Japan? How is the market divided into different product segments? Which ...
July 2013
22 pages
Gasoline and Oil Additive Market in Japan to 2017 - Market Size, Trends, and Forecasts
US$ 653.00
... until 2017 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for ... QUESTIONS SUCH AS: What is the size of the gasoline and oil additive market in Japan? How is the market divided into different product segments? ...
July 2013
22 pages
2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Endocrine Function Testing Market in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... TPO Ab and TSH. During the next five years, the endocrine function testing market will undergo significant transformation. These changes will ... , such as specimen preparation devices, controls, calibrators and others. “2013 Endocrine Function Testing Market in Japan: Hospitals and Commercial Labs” is a unique ...
June 2013
269 pages
MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth
US$ 140.00
Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are future drivers of Morphosys (MOR). After selling ... detail, please read our report released on June 05, 2013, titled, “MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth”.
June 2013
5 pages
2013 Therapeutic Drug Monitoring (TDM) Market in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Japan: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...
June 2013
247 pages
2013 Immunoprotein Diagnostic Testing in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “Immunoprotein Diagnostic Testing in Japan: Hospitals and Commercial Labs” is a unique market and technology assessment designed to help current suppliers and potential ...
June 2013
234 pages
Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside
US$ 140.00
... drugs) has gained 50% of market share in 16 months of launch showing acceptability of Halozyme’s (HALO) ENHANZE platform (recombinant human hyaluronidase, rHuPH20 use in the ... detail, please read our report released on May 24, 2013, titled, “HyQvia Approval in EU and Upcoming milestones = Upside”.
May 2013
4 pages
Diagnostic Testing in Japan: Market Segment Forecasts and Supplier Shares
US$ 3,880.00
... from Venture Planning Group provides an overview of the Japanese diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for the following market segments: Blood Banking Cancer Chemistry Coagulation ...
May 2013
60 pages
Japanese Clinical Chemistry and Immunodiagnostic Market Outlook: Innovations, Trends and Opportunities for Suppliers
US$ 6,080.00
... markets, including: Major issues pertaining to the Japanese clinical chemistry and immunodiagnostic laboratory practice, as well as key economic, regulatory, demographic, social ... ten-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays ...
May 2013
559 pages
Japan Pharma Database
US$ 15,000.00
Pricing: Japan Database: $15,000/- subscription p/a Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets ... reliable Source in public domain 5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas ...
April 2013
-
2013 Analysis of the Japanese Infectious Disease Testing Market: Emerging Opportunities, Supplier Shares, Country Forecasts, Innovative Technologies, and Competitive Landscape
US$ 7,040.00
This report presents a comprehensive analysis of the Japanese infectious disease testing market, including: Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...
April 2013
976 pages
2013 Analysis of the Japanese Molecular Diagnostics Market: Emerging Opportunities, Supplier Shares, Country Forecasts, Innovative Technologies, and Competitive Landscape
US$ 6,800.00
This report presents a comprehensive analysis of the Japanese molecular diagnostics market, including: Major issues pertaining to the Japanese molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the ...
April 2013
860 pages
